Disease incidences are rapidly escalating across the globe and few rare diseases have emerged for which effective medications are not available. Occurrence of such disease is not unusual and their roots could be traced back to genetic or metabolic anomalies. They affect limited number of individuals and widely uncommon in nature. Such diseases are called rare diseases and corresponding drugs are known as orphan drugs. The orphan drug status to a particular formulation depends upon the public health policy due to which number of individuals may vary from country to country.

The Global Irbesartan Industry Report 2015 is a professional and in-depth study on the current state of the Irbesartan industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Irbesartan market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

GLOBAL TRANSDERMAL DRUG DELIVERY MARKET TO 2017 Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. This report is presented as follows:

• By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
• By Geography (Global, USA)